S&P 500   3,913.67 (+0.83%)
DOW   31,843.95 (+0.97%)
QQQ   322.09 (+0.19%)
AAPL   124.71 (-0.91%)
MSFT   232.28 (-0.42%)
FB   263.90 (-0.74%)
GOOGL   2,071.11 (+0.53%)
AMZN   3,160.06 (-1.08%)
TSLA   733.90 (+5.02%)
NVDA   565.41 (-0.05%)
BABA   250.55 (-0.87%)
CGC   36.13 (+2.32%)
GE   13.25 (+5.24%)
MU   90.75 (+2.86%)
NIO   51.54 (+4.95%)
AMD   85.02 (+0.33%)
T   29.46 (+0.96%)
F   12.02 (+3.44%)
ACB   11.65 (+3.93%)
DIS   200.09 (+1.52%)
BA   224.57 (+5.87%)
NFLX   553.08 (+1.27%)
BAC   36.27 (+2.11%)
S&P 500   3,913.67 (+0.83%)
DOW   31,843.95 (+0.97%)
QQQ   322.09 (+0.19%)
AAPL   124.71 (-0.91%)
MSFT   232.28 (-0.42%)
FB   263.90 (-0.74%)
GOOGL   2,071.11 (+0.53%)
AMZN   3,160.06 (-1.08%)
TSLA   733.90 (+5.02%)
NVDA   565.41 (-0.05%)
BABA   250.55 (-0.87%)
CGC   36.13 (+2.32%)
GE   13.25 (+5.24%)
MU   90.75 (+2.86%)
NIO   51.54 (+4.95%)
AMD   85.02 (+0.33%)
T   29.46 (+0.96%)
F   12.02 (+3.44%)
ACB   11.65 (+3.93%)
DIS   200.09 (+1.52%)
BA   224.57 (+5.87%)
NFLX   553.08 (+1.27%)
BAC   36.27 (+2.11%)
S&P 500   3,913.67 (+0.83%)
DOW   31,843.95 (+0.97%)
QQQ   322.09 (+0.19%)
AAPL   124.71 (-0.91%)
MSFT   232.28 (-0.42%)
FB   263.90 (-0.74%)
GOOGL   2,071.11 (+0.53%)
AMZN   3,160.06 (-1.08%)
TSLA   733.90 (+5.02%)
NVDA   565.41 (-0.05%)
BABA   250.55 (-0.87%)
CGC   36.13 (+2.32%)
GE   13.25 (+5.24%)
MU   90.75 (+2.86%)
NIO   51.54 (+4.95%)
AMD   85.02 (+0.33%)
T   29.46 (+0.96%)
F   12.02 (+3.44%)
ACB   11.65 (+3.93%)
DIS   200.09 (+1.52%)
BA   224.57 (+5.87%)
NFLX   553.08 (+1.27%)
BAC   36.27 (+2.11%)
S&P 500   3,913.67 (+0.83%)
DOW   31,843.95 (+0.97%)
QQQ   322.09 (+0.19%)
AAPL   124.71 (-0.91%)
MSFT   232.28 (-0.42%)
FB   263.90 (-0.74%)
GOOGL   2,071.11 (+0.53%)
AMZN   3,160.06 (-1.08%)
TSLA   733.90 (+5.02%)
NVDA   565.41 (-0.05%)
BABA   250.55 (-0.87%)
CGC   36.13 (+2.32%)
GE   13.25 (+5.24%)
MU   90.75 (+2.86%)
NIO   51.54 (+4.95%)
AMD   85.02 (+0.33%)
T   29.46 (+0.96%)
F   12.02 (+3.44%)
ACB   11.65 (+3.93%)
DIS   200.09 (+1.52%)
BA   224.57 (+5.87%)
NFLX   553.08 (+1.27%)
BAC   36.27 (+2.11%)
Log in

Needham & Company LLC's rating of Revance Therapeutics, Inc. on 1/8/2021

unlock icon Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.